ClinicalTrials.gg
CompletedNCT00424047Updated Oct 19, 2017Results posted

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

A Phase 3 interventional study of CC-5013 plus dexamethasone and Dexamethasone plus Placebo in Multiple Myeloma, sponsored by Celgene. Completed at 69 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Jan 2003, registered Jan 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
30th of 249
351 · median 50
Started
2003
with 3 others
Phase 3
44 of 249
3 open now
Registered
23rd of 249
by date
Lead sponsor
14 of 249
Celgene

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 30th largest by enrollment, is one of 4 that started in 2003, is one of 44 in phase 3, and was the 23rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for subjects with relapsed or refractory multiple myeloma."

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Celgene
  • Revlimid
  • CC-5013
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.
  • Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).
  • (ECOG) performance status score of 0,1, or 2
  • Females of must have a negative serum or urine pregnancy test within 7 days of starting study drug

Exclusion criteria

Exclusion Criteria:

  • Prior development of disease progression during high-dose dexamethasone containing therapy
  • Pregnant or lactating females
  • The development of a desquamating rash while taking thalidomide
  • Use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment
  • Laboratory abnormalities: less than 1,000 cells/mm3
  • Laboratory abnormalities: count \< 75,000/mm3
  • Laboratory abnormalities: Serum creatinine > 2.5 mg/dL
  • Laboratory abnormalities: Serum Serum glutamic oxaloacetic transaminase ()/Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT) > 3.0 x
  • Laboratory abnormalities: Serum total > 2.0 mg/dL
  • Prior history of other than multiple myeloma unless the subject has been free of the disease for ≥ 3 years.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    CC-5013 plus dexamethasone

    Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.

    Drug: CC-5013 plus dexamethasone

  • Experimental
    Dexamethasone plus placebo

    Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.

    Drug: Dexamethasone plus Placebo

Interventions

  • DrugCC-5013 plus dexamethasone

    Drug pages: Lenalidomide · Dexamethasone

    25 mg daily for 21 days every 28 days.

    Also known as: Revlimid, lenalidomide

  • DrugDexamethasone plus Placebo

    Drug page: Dexamethasone

    Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.

    Also known as: Dexamethasone, Placebo

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimate of Time to Tumor Progression (TTP)

    Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: From randomization up to cut-off date of 03 August 2005; up to 24 months

  2. Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)

    Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: From randomization up to cut-off date of 02 March 2008; up to 51 months

Secondary outcomes

  1. Kaplan-Meier Estimate of Overall Survival (OS)

    OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: Randomization to data cut off of 03 August 2005; up to 24 months

  2. Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)

    OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: Randomization to data cut off of 02 March 2008; up to 51 months

  3. Summary of Myeloma Response Rates Based on Best Response Assessment

    Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.

    Time frame: Randomization to 03 August 2005; up to 24 months

  4. Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)

    Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.

    Time frame: Randomization to data cut-off of 02 Mar 2008; up to 51 months

  5. Number of Participants With Adverse Events (AE)

    An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.

    Time frame: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months

  6. Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)

    Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).

    Time frame: Up to unblinding data cut off of 03 August 2005; up to 24 months

  7. Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale

    The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.

    Time frame: Randomization to cut off date of 03 August 2005; up to 24 months

  8. Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)

    The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.

    Time frame: Randomization to cut off date of 02 March 2008; up to 51 months

07

Results

Posted Mar 4, 2015

Participant flow

The study was conducted at 55 sites in Australia, Europe, and Israel. Eligible participants were randomized in a 1:1 ratio to: lenalidomide plus oral pulse high-dose dexamethasone or Placebo plus oral pulse high-dose dexamethasone.

Blinded Treatment (Up to 03 Aug 2005)
Participant flow — Blinded Treatment (Up to 03 Aug 2005)
MilestoneLenalidomide Plus Dexamethasone (Len/Dex)Placebo Plus Dexamethasone
Started176175
Safety population176175
Evaluable population175171
Completed5419
Not completed122156
Withdrew: Adverse event1812
Withdrew: Progression of disease67122
Withdrew: Lack of therapeutic effect13
Withdrew: Withdrawal by subject238
Withdrew: Death1110
Withdrew: Other21
On Study at Time of Unblinding
Participant flow — On Study at Time of Unblinding
MilestoneLenalidomide Plus Dexamethasone (Len/Dex)Placebo Plus Dexamethasone
Started176175
Completed218
Not completed155167
Withdrew: Adverse event2212
Withdrew: Progression of disease92128
Withdrew: Lack of efficacy13
Withdrew: Withdrawal by subject249
Withdrew: Death1111
Withdrew: Other54
Long Term Extension (Up to 25 Jun 2013)
Participant flow — Long Term Extension (Up to 25 Jun 2013)
MilestoneLenalidomide Plus Dexamethasone (Len/Dex)Placebo Plus Dexamethasone
Started218
Completed00
Not completed218
Withdrew: Adverse event10
Withdrew: Death01
Withdrew: Other124
Withdrew: Progression of disease73
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryKaplan-Meier Estimate of Time to Tumor Progression (TTP)

Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
From randomization up to cut-off date of 03 August 2005; up to 24 months
Reported as:
Median · weeks
Kaplan-Meier Estimate of Time to Tumor Progression (TTP)
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Kaplan-Meier Estimate of Time to Tumor Progression (TTP)52.1 (40.9 to NA)20.1 (16.6 to 20.7)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = <0.001 · Hazard ratio (hr): 0.324 · 95% CI 0.240 to 0.438Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (Lenalidomide/Dex:Placebo/Dexamethasone)
SecondaryKaplan-Meier Estimate of Overall Survival (OS)

OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
Randomization to data cut off of 03 August 2005; up to 24 months
Reported as:
Median · weeks
Kaplan-Meier Estimate of Overall Survival (OS)
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Kaplan-Meier Estimate of Overall Survival (OS)NA (NA to NA)NA (71.6 to NA)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = 0.105 · Hazard ratio (hr): 0.730 · 95% CI 0.498 to 1.070Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (Lenalidomide/Dexamethasone:Placebo/Dexamethasone)
SecondaryKaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)

OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
Randomization to data cut off of 02 March 2008; up to 51 months
Reported as:
Median · weeks
Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)161.9 (129.3 to 201.4)133.3 (101.6 to 174.0)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = 0.302 · Hazard ratio (hr): 0.863 · 95% CI 0.651 to 1.143Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)
SecondarySummary of Myeloma Response Rates Based on Best Response Assessment

Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.

Time frame:
Randomization to 03 August 2005; up to 24 months
Reported as:
Number · percentage of participants
Summary of Myeloma Response Rates Based on Best Response Assessment
percentage of participantsLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Complete Response (CR)15.34.0
Partial Response (PR)43.819.4
Stable Disease (SD)29.056.6
Progressive Disease (PD)2.814.3
Not Evaluable (NE) those without response data9.15.7
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Wilcoxon (Mann-Whitney) · p = <0.001Probability from Wilcoxon rank sum test
SecondaryMyeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)

Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.

Time frame:
Randomization to data cut-off of 02 Mar 2008; up to 51 months
Reported as:
Number · percentage of participants
Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)
percentage of participantsLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Complete Response (CR)17.04.0
Partial Response (PR)42.619.4
Stable Disease (SD)28.456.6
Progressive Disease (PD)3.414.3
Not Evaluable (NE) those without response data8.55.7
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Wilcoxon (Mann-Whitney) · p = <0.001Probability from Wilcoxon rank sum test
SecondaryNumber of Participants With Adverse Events (AE)

An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.

Time frame:
From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
≥ 1 Adverse Event176175
≥ 1 Serious Adverse Event10579
≥ 1 AE leading to study drug discontinuation4631
≥ 1 AE leading to dose reduction or interruption137100
≥ 1 Drug-Related Adverse Event160151
≥ 1 Drug-Related Serious Adverse Event5430
≥Death within ≤ 30 days of last dose of study drug1720
≥ 1 Grade 1 or Higher Adverse Event176175
≥ 1 Grade 2 or Higher Adverse Event168167
≥ 1 Grade 3 or Higher Adverse Event146119
≥ 1 Grade 4 or Higher Adverse Event5237
SecondaryTime to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)

Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).

Time frame:
Up to unblinding data cut off of 03 August 2005; up to 24 months
Reported as:
Number · participants
Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)
participantsLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)NANA
Post-hocKaplan-Meier Estimate of Duration of Response

Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.

Time frame:
Up to data cut off of 03 August 2005; up to 24 months
Reported as:
Median · weeks
Kaplan-Meier Estimate of Duration of Response
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Kaplan-Meier Estimate of Duration of Response67.6 (42.1 to NA)33.3 (22.1 to 51.6)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = 0.021 · Hazard ratio (hr): 0.558 · 95% CI 0.338 to 0.921Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (lenalidomide/dexamethasone : placebo/dexamethasone).
PrimaryKaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)

Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
From randomization up to cut-off date of 02 March 2008; up to 51 months
Reported as:
Median · weeks
Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)52.4 (40.9 to 85.6)20.1 (16.6 to 20.7)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = <0.001 (The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.) · Hazard ratio (hr): 0.362 · 95% CI 0.27 to 0.478Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)
SecondaryTime to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale

The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.

Time frame:
Randomization to cut off date of 03 August 2005; up to 24 months
Reported as:
Median · weeks
Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale10.1 (8.1 to 16.1)12.3 (10.1 to 24.1)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = 0.271 (The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.) · Hazard ratio (hr): 1.166 · 95% CI 0.887 to 1.532Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (lenalidomide/dexamethasone: placebo/dexamethasone)
SecondaryTime to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)

The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.

Time frame:
Randomization to cut off date of 02 March 2008; up to 51 months
Reported as:
Median · weeks
Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)10.1 (8.1 to 16.1)12.3 (10.1 to 24.1)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = 0.359 (The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.) · Hazard ratio (hr): 1.135 · 95% CI 0.866 to 1.486Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)
Post-hocKaplan-Meier Estimate of Duration of Response (Cut-off at a Later Date of 03 March 2008)

Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.

Time frame:
Up to data cut off of 03 Mar 2008; up to 51 months
Reported as:
Median · weeks
Kaplan-Meier Estimate of Duration of Response (Cut-off at a Later Date of 03 March 2008)
weeksLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
Kaplan-Meier Estimate of Duration of Response (Cut-off at a Later Date of 03 March 2008)68.1 (42.1 to 105.6)33.3 (22.1 to 51.6)
Statistical analysis
  • Lenalidomide Plus Dexamethasone vs Placebo Plus Dexamethasone · Log Rank · p = 0.032 · Hazard ratio (hr): 0.619 · 95% CI 0.398 to 0.964Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)

Adverse events

Collected over From first dose of study drug to 30 days after the last visit. Up to 25 Jun 2013 (90 Months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide Plus Dexamethasone—105/176 (59.7%)175/176 (99.4%)
Placebo Plus Dexamethasone—79/175 (45.1%)173/175 (98.9%)
Most frequent serious events
Showing 10 of 195
Most frequent serious events
EventLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
PNEUMONIA NOSInfections and infestations11/1767/175
DEEP VEIN THROMBOSISVascular disorders8/1766/175
RESPIRATORY TRACT INFECTION NOSInfections and infestations4/1767/175
PYREXIAGeneral disorders6/1767/175
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders7/1762/175
BACK PAINMusculoskeletal and connective tissue disorders5/1761/175
BONE PAINMusculoskeletal and connective tissue disorders5/1760/175
RENAL FAILURE NOSRenal and urinary disorders3/1764/175
UPPER RESPIRATORY TRACT INFECTION NOSInfections and infestations4/1760/175
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders4/1761/175
Most frequent other events
Showing 10 of 76
Most frequent other events
EventLenalidomide Plus DexamethasonePlacebo Plus Dexamethasone
NEUTROPENIABlood and lymphatic system disorders71/17617/175
CONSTIPATIONGastrointestinal disorders71/17641/175
DIARRHOEA NOSGastrointestinal disorders67/17645/175
ASTHENIAGeneral disorders64/17646/175
INSOMNIAPsychiatric disorders51/17663/175
MUSCLE CRAMPMusculoskeletal and connective tissue disorders56/17636/175
ANAEMIABlood and lymphatic system disorders52/17649/175
FATIGUEGeneral disorders51/17641/175
PYREXIAGeneral disorders50/17640/175
WEIGHT DECREASEDInvestigations49/17646/175

Baseline characteristics

Intent to treat population included all participants who were randomized

Age, Continuous
Age, Continuous(years)Lenalidomide Plus DexamethasonePlacebo Plus DexamethasoneTotal
Mean62.2 ± 10.1262.9 ± 8.8062.6 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide Plus DexamethasonePlacebo Plus DexamethasoneTotal
Female7272144
Male104103207
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Lenalidomide Plus DexamethasonePlacebo Plus DexamethasoneTotal
0 = (Fully Active)7865143
1 = (Restrictive but Ambulatory)7279151
2 = Ambulatory unable to Work)232750
3 = (Limited Self-Care)011
4 = (Completely Disabled)000
Missing336
Number of Prior Anti-Myeloma Therapies
Number of Prior Anti-Myeloma Therapies(participants)Lenalidomide Plus DexamethasonePlacebo Plus DexamethasoneTotal
1 Prior anti-myeloma therapy5657113
2 or more prior anti-myeloma therapies120118238
Time from First Pathological Diagnosis
Time from First Pathological Diagnosis(years)Lenalidomide Plus DexamethasonePlacebo Plus DexamethasoneTotal
Median3.4 (0.4 to 15.7)4.0 (0.3 to 26.6)3.7 (0.3 to 26.6)
Baseline multiple myeloma stage
Baseline multiple myeloma stage(participants)Lenalidomide Plus DexamethasonePlacebo Plus DexamethasoneTotal
Stage I11819
Stage II5057107
Stage III115110225
08

Study locations

69 sites
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Peter MacCallum Cancer Centre Divsion of Haematology/Medical Oncology
    East Melbourne, Victoria 3006, Australia
  • The Alfred Hospital
    Prahran, Victoria 3121, Australia
  • Border Medical Oncology
    Wodonga, Victoria 3690, Australia
  • Box Hill Hospital
    Box Hill, VIC 3128, Australia
  • Frankston Hospital Oncology Research
    Frankston, VIC 3199, Australia
  • Royal Brisbane Hospital
    Herston, QLD4029, Australia
  • The Royal Melbourne Hospital
    Parkville, 3050, Australia
  • Mater Public Hospital
    South Brisbane, QLD 4101, Australia
  • University Hospital of Salzburg St Johanns Spital
    Salzburg, A -5020, Austria
  • Wilhelminenspital
    Vienna, 1160, Austria
  • CHU Saint-Luc
    Brussels, 1200, Belgium
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • Centre Hospitalier Lyon Sud
    Chemin Grand Revoyet, 69495 Pierre Benite cedex, France
  • Hopital Claude Huriez
    Lille, 59037, France
  • Centre Hospitalier Hotel-Dieu
    Nantes, France
  • Hopital Saint-Loius
    Paris, 75010, France
  • Chu de Bordeaux Groupe Hospitalier Sud
    Pessac, 33640, France
  • CHU Purpan
    Toulouse, TSA 40031-31059, France
  • CHU Nancy - Hopital Brabois
    Vandœuvre-lès-Nancy, 54511, France
  • Universitaetsklinikum Charite
    Berlin, 13125, Germany
  • Universitatsklinik ChariteMedizinische Fakultaet der HumboldtUniversitaet zu Berlin
    Berlin, 13353, Germany
  • Universitaetsklinikum Dusseldorf Klinik fuer Haematologie
    Düsseldorf, 40225, Germany
  • Universitaetsklinkum Erlangen
    Erlangen, 91054, Germany
  • Klininkum der Johann-Wolfgang-Goethe-Universtat
    Frankfurt am Main, 60590, Germany
  • Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V
    Heidelberg, 69120, Germany
  • Klinikum der Univeristact Muenchen
    München, 80336, Germany
  • Universitatsklinik Muenster Medizinische Klinik A
    Münster, 48129, Germany
  • Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
  • "Alexandras" General Hospital of Athens
    Athens, 11538, Greece
  • University Hospital GalwayHaematology Department
    Galway, Co. Galway, Ireland
  • Belfast City HospitalHaematology Department
    Belfast, BT9 7AB, Ireland
  • Hope Directorate Haematology Oncology Service St. James Hospital
    Dublin, Ireland
  • MidWestern Regional Hospital
    Limerick, Ireland
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Hadassah University Hospital
    Jerusalem, Israel
  • Tel Aviv Sourasky Medical Center Department of Hematology
    Tel Aviv, 64239, Israel
  • The Chaim Sheba Medical Center
    Tel Litwinsky, 52621, Israel
  • Policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliera San Martino
    Genova, 16132, Italy
  • Ospedale Niguarda Ca Granda
    Milan, 20162, Italy
  • Policlinico San Matteo
    Pavia, 27100, Italy
  • Univerita La Sapien
    Roma, 00161, Italy
  • Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista
    Torio, 10126, Italy
  • Policlinico Universitario a Gesttione diretta di Udine
    Udine, 33100, Italy
  • Institute of Internal Diseases University of Medicine
    Gdansk, 80-211, Poland
  • University School of Medicine
    Lublin, 20-290, Poland
  • Institute of Haematology and Blood Transfusion
    Warsaw, 00-957, Poland
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital Universitario de la Princessa
    Madrid, 28006, Spain
  • Hospital Doce de Octubre
    Madrid, 28041, Spain
  • Clinica Universitaria de Navarra
    Pamplona, 31080, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universtario Marques de Valdecilla
    Santander, 39008, Spain
  • Sahlgrenska University Hospital Department of Hematology and Coagulation
    Gothenburg, S-413 45, Sweden
  • Centre Hospitalier Universitaire Vaudois (CHUV)
    Lausanne, 1011, Switzerland
  • Kantonsspital St. Gallen
    Sankt Gallen, Switzerland
  • Universitätsspital Zürich
    Zurich, 8091, Switzerland
  • Cherkassy Regional Oncology Center
    Cherkassy, 18009, Ukraine
  • Dnepropetrovsk City Clinical Hospital #4
    Dnipro, 49044, Ukraine
  • Kiev Bone Marrow Transplantation Center Bone Marrow Department
    Kiev, 03115, Ukraine
  • Institute of Hematology and Transfusiology of the UAMS Department of blood diseases
    Kiev, 04060, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department
    Lviv, 79044, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine of the UAMS
    Lviv, 79044, Ukraine
  • Odess Regional Clinical Hospital
    Odesa, 65025, Ukraine
  • Zhitomir Regional Clinical Hospital
    Zhytomyr, 10003, Ukraine
  • University College Hospital Trust
    London, Bloomsbury WC1E 6AU, United Kingdom
  • Bristol Haematology and Oncology Centre
    Bristol, BS2 8ED, United Kingdom
  • Haematology Dept, 4th Floor Thomas Guy House
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594. PubMed 18032762 ↗
  • San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120. PubMed 21273172 ↗
  • Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 1;28(1):132-5. doi: 10.1200/JCO.2009.23.0169. Epub 2009 Nov 9. PubMed 19901114 ↗
  • Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17. PubMed 18799726 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2003 to primary completion in Nov 2005, 34 months.

Results were first posted in Mar 2015, 9 years 4 months after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 34 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 18, 2007
StartActual
Jan 1, 2003
Primary completionActual
Nov 1, 2005
CompletionActual
Nov 12, 2013
Results first posted
Mar 4, 2015
Last update
Oct 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424047
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Jan 1, 2003
Primary completion
Nov 1, 2005
Completion
Nov 12, 2013
Results posted
Mar 4, 2015
Last update
Oct 19, 2017

Study contacts

Robert Knight, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion